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Receptor activator of nuclear factor-kappa B ligand (RANKL) is a member of tumor necrosis factor (TNF) superfamily that
plays a key role in the regulation of differentiation, activation and survival of osteoclasts and also in tumor cell migration
and bone metastasis. Osteoclast activation induced by RANKL regulates hematopoietic stem cell mobilization as part of
homeostasis and host defense mechanisms thereby linking regulation of hematopoiesis with bone remodeling. Binding of
RANKL to its receptor, Receptor activator of nuclear factor-kappa B (RANK) activates molecules such as NF-kappa B, mito-
gen activated protein kinase (MAPK), nuclear factor of activated T cells (NFAT) and phosphatidyl 3-kinase (PI3K). Although
the molecular and cellular roles of these molecules have been reported previously, a systematic cataloging of the molecular
events induced by RANKL/RANK interaction has not been attempted. Here, we present a comprehensive reaction map of
the RANKL/RANK-signaling pathway based on an extensive manual curation of the published literature. We hope that the
curated RANKL/RANK-signaling pathway model would enable new biomedical discoveries, which can provide novel insights
into disease processes and development of novel therapeutic interventions.
Database URL: http://www.netpath.org/pathways?path_id=NetPath_21
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Introduction
The paracrine system involved in many tissues includes nu-
merous cytokines and growth factors necessary for the dif-
ferentiation and maturation of cells of which amongst
tumor necrosis factor (TNF) family assumes a vital role.
The TNF superfamily consists of numerous ligand/receptor
proteins involved in various cellular processes such as devel-
opment, homeostasis and apoptosis. RANKL, also known as
TNFSF11, osteoprotegerin ligand, TNF-related activation-
induced cytokine (TRANCE) or osteoclast differentiation
factor, is a member of the TNF superfamily (1). The mem-
brane bound form of RANKL is a type II transmembrane
glycoprotein with an extracellular region, a transmem-
brane domain and an intracellular cytoplasmic region (2).
RANKL also exist in a soluble form derived either through
an alternative splicing event or by the proteolytic cleavage
of the membrane anchoring domain of RANKL by a
membrane-associated metalloprotease, such as TNF con-
verting enzyme, matrix metalloproteinase 14, matrix metal-
loproteinase 7 or Disintegrin and metalloproteinase
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family, RANK is expressed mainly on cells of monocyte/
macrophage lineage such as pro-osteoclasts and osteo-
clasts, whereas the RANKL is synthesized by and expressed
on cell membrane of bone marrow stromal cell and osteo-
blasts. Expression of RANKL has also been detected in a
wide variety of tissues and specific cells including spleen,
placenta, heart, stomach, thyroid gland, lung, brain, thy-
mus, lymph nodes, osteoclasts and peripheral blood leuko-
cytes (7–10). In bone metabolism, osteoclasts play primary
role by involving in bone resorption. In brain, RANKL is ex-
pressed in the lateral septal nucleus and RANK is expressed
specifically in the neurons and astrocytes of the preoptic
area and medial septal nucleus in the hypothalamus.
Hanada et al. (11) have shown a novel function of
RANKL/RANK signaling in brain that plays a significant
role in the regulation of body temperature and fever re-
sponse in inflammation. Prolactin, progesterone and para-
thyroid hormone-like related protein stimulate RANKL
expression on mammary gland epithelial cells whereas
RANK is constitutively expressed in these cells. Knockout
studies in mice have shown that RANKL and RANK are
required for the development, proliferation and survival
of lactating mammary gland during pregnancy. RANKL/
RANK-signaling system is critical for the induction of lacta-
tion by mediating lobulo-alveloar morphogenesis. Kim
et al., have also shown that RANK activation by RANKL is
crucial to control proliferation of mammary epithelial cells
(12,13). Furthermore, RANKL is reported to be upregulated
in primary malignant bone tumors including osteosarcoma,
chondrosarcoma, giant cell tumor (14) and multiple mye-
loma (15). RANKL has also been shown to be overexpressed
in >90% of metastatic tumor cells in adenocarcinoma le-
sions of prostate, breast, lung and thyroid origin (16) and
also in breast cancer stromal cells (17).
RANKL binds to type I transmembrane protein known as
RANK (TNFRSF11A) to form a functional hexamer complex
containing trimeric RANKL and RANK (18–20). The RANKL/
RANK interaction is essential to osteoclastogenesis as it
stimulates the differentiation, maturation and survival
of osteoclasts (21–25). In the immune system, RANKL ex-
pressed by activated T cells interacts with RANK expressed
on dendritic cells in order to regulate survival and function
of dendritic cells (10,26–28). RANKL/RANK system plays an
important role in controlling the development of AIRE
+
thymic medullary epithelial cells in the thymus (29) and in
lymph node organogenesis (30). Osteoprotegerin (OPG),
also known as (TNFRSF11B) or osteoclastogenesis inhibitory
factor, is a decoy receptor that modulates signaling by
RANKL during osteoclastogenesis. OPG binds to RANKL
and neutralizes its function thereby negatively regulating
osteoclast differentiation, maturation and survival (31,32).
Undifferentiated pre-osteoblastic bone marrow stromal
cells were known to express high levels of RANKL along
with relatively low levels of OPG. The ratio of RANKL/OPG
increases during their activation and differentiation into
osteoclasts. This ratio declines during differentiation of
undifferentiated pre-osteoblastic cells into mature osteo-
blasts during which their osteoclastogenic activity is sup-
pressed (33). Thus the RANKL/OPG ratio plays a significant
role in determining bone mass and skeletal integrity. RANK,
being a member of TNF receptor superfamily, lacks any
catalytic activity and therefore recruits adaptor molecules
such as TNFR-associated factors (TRAFs) to transduce signals.
Several pathways have been shown to be activated by
RANKL/RANK-signaling system. These pathways include,
NF-kappa B, mitogen activated protein kinases (MAPK’s),
protein kinase C (PKC), Ca2+/Calcineurin/nuclear factor of
activated T cells (NFAT) and phosphoinositide-3-kinase
(PI3K). The functional importance of NF-kappa B (34–40),
JNK (41–44), SRC-PI3K-AKT (45,46) and p38MAPK (47) path-
ways in osteoclast differentiation and osteoclastogenesis
have been extensively studied. Although the RANKL/
RANK pathway has been well studied, a comprehensive
map of this signaling pathway is not available in any of
the publicly available signal transduction pathway re-
sources. Our group has previously developed a signaling
pathway resource called NetPath (http://www.netpath.
org), which currently comprises of 20 human signaling
pathways involved in immune- and cancer-signaling path-
ways (48). With the goal of creating manually curated indi-
vidual pathways relevant to molecular biologists and
clinicians alike, we describe here the development of a
comprehensive resource of RANKL/RANK-signaling path-
way. Similar approaches were previously undertaken by
various groups to provide comprehensive maps of epider-
mal growth factor receptor (49), interleukin-1 receptor (50)
and toll-like receptor (51) signaling pathways. RANKL/
RANK-signaling pathway resource is a NetPath module
freely available at http://www.netpath.
org/pathways?path_id=NetPath_21.
Curation of RANKL pathway
reactions
An extensive curation of scientific literature was carried
out to catalog RANKL/RANK stimulated reactions. The reac-
tions in NetPath collectively represent individual biochem-
ical events such as protein–protein interactions (PPIs),
enzyme–substrate reactions or protein translocation events.
We have cataloged these reactions which are proved to be
induced or enhanced by the RANKL–RANK interaction. The
curation of RANKL pathway reactions was based on the
following criteria: (i) reactions should be stimulated by
RANKL/RANK system, (ii) reactions must be either induced
or enhanced in vivo, (iii) proteins involved in reactions
should be from human system, however other mammalian
.............................................................................................................................................................................................................................................................................................
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human system (The mammalian proteins should have
orthologous proteins identified in human), (iv) reactions
if stimulated by multiple ligands were not considered
and (v) only experiments carried out in cell lines of mam-
malian origin were considered. We used PathBuilder (52),
a curation tool previously developed by our group, to
annotate pathway reactions captured in this curation
process.
PPIs
PPIs are important mediators and regulators of signaling.
We have curated PPIs reported in literature for RANKL/
RANK-signaling system as direct or complex interactions.
Direct interactions represent interaction between two mol-
ecules whereas complex interactions represent the exist-
ence of more than two molecules as a complex. We have
also curated various features pertaining to these PPIs
including domains and motifs involved in the interaction,
dependence of the reactions on various post-translational
modifications (PTMs), subcellular location of the interac-
tion and also the cell type in which the reactions were
reported.
Enzyme–substrate reactions
PTMs are known to regulate signaling cascades by altering
functional properties and recruiting proteins to subcellular
compartments. We have captured several events of phos-
phorylation, dephosphorylation, ubiquitination and pro-
teolytic cleavage in RANKL/RANK-signaling pathway. We
could not capture any study specific to other PTMs such
as sumoylation, desumoylation, deubiquitination, acetyl-
ation, deacetylation, methylation, demethylation, pal-
mitoylation and glycosylation reactions in RANKL/RANK-
signaling pathway. We cataloged these reactions as either
direct or indirect catalytic events. Whenever the upstream
enzymes responsible for modification were reported in the
literature, PTMs are curated as direct. However, induced/
indirect represents PTMs on proteins for which no report
is available on the upstream enzyme responsible for the
modification. We documented the enzyme–substrate reac-
tions responsible for direct catalysis events also as PPIs.
Whenever available in the literature, we have also cata-
loged the site and residue information of the PTMs and
mapped these on to the respective protein sequences
provided in RefSeq database. The molecules which are re-
ported to be activated or inhibited by various assays such as
GTPase assay or kinase activity assay but their PTM status
has not been reported in RANKL signaling are cataloged
into activation/inhibition reactions.
Protein translocation events
During signal transduction, proteins translocate across sub-
cellular compartments or are secreted into the extracellular
space, a fate determined by interaction partners, various
PTMs, or a specific regulatory event. We have curated trans-
location events in RANKL pathway along with their PTM
dependence and description of the experimental system
of observation. We used Gene Ontology (GO) to define
subcellular localization (53).
Gene regulation
We have cataloged transcriptionally regulated genes by
RANKL/RANK signaling from normal human cells. The cata-
loging involves the identification and curation of genes dif-
ferentially regulated by RANKL signaling reported in
literature as demonstrated using diverse experimental stra-
tegies including DNA microarrays, northern blot, serial ana-
lysis of gene expression and quantitative RT–PCR. The cells/
cell types in which the genes are identified to be differen-
tially regulated are also curated. In addition, we have also
documented transcriptional regulators of the differentially
regulated genes.
Summary of RANKL/RANK
pathway curation
Our manual literature survey on RANKL/RANK-signaling
pathway has cataloged 88 molecules involved in 73 PPIs,
59 enzyme–substrate reactions and 10 protein translocation
events. PPIs include 58 binary interactions and 15 protein
complexes. The 59 enzyme–substrate reactions comprise
of 14 direct reactions which were also considered as direct
PPIs and 45 RANKL induced catalytic reactions. We have
also cataloged 74 genes which are differentially regulated
at the mRNA level by RANKL signaling in various cell types
in human system. The interaction domains or motifs for
14 proteins in this pathway have also been documented.
The site and residue information for PTMs were captured
for 17 proteins. We annotated transcriptional regulators
for eight differentially regulated genes from our litera-
ture survey pertaining to studies on RANKL pathway.
Each and every pathway reactions annotated in NetPath
were linked to scientific articles. Six PPIs which were
not available in HPRD were submitted to HPRD (54). All
the RANK receptor activated reactions were reviewed by
a pathway authority (http://www.netpath.org/pathway_
authority?path_id=NetPath_21). We have captured several
molecules associated with RANKL signaling but not in-
cluded in the review articles on this pathway to the best
of our knowledge. These molecules include FHL2, LYN,
FYN, PTK2, ATP6V1E1, ETV5, CYLD, SQSTM1 and LIMD1.
We hope that future review articles will consider the add-
ition of these proteins while describing RANKL/RANK
signaling.
.............................................................................................................................................................................................................................................................................................
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RANK-signaling pathway
Multiprotein complexes, not individual proteins, are in-
creasingly being recognized as the molecular basis of cellu-
lar fluxes of signals. Thus, the identification of dynamic
protein complexes is of major interest to the experimental
as well as computational biologists. The current effort on
RANKL/RANK-signaling system has cataloged several such
protein complexes. These complexes are enlisted in Table 1.
There were seven protein complexes which were associ-
ated with RANK and seven complexes with TRAF6 as a
constituent.
Data formats and availability
The RANKL pathway data described in this work is inte-
grated into NetPath which is publicly available at (http://
www.netpath.org). NetPath RANKL pathway page provides
a summary of the pathway, statistics of the number of mol-
ecules and total reactions curated under different data
categories such as physical interactions, enzyme catalysis,
transport and gene regulation. An overview of the
RANKL/RANK pathway page in NetPath with the curated
information on PPIs, enzyme catalysis and PTMs, protein
translocation reactions and gene regulation is provided in
Figure 1. The annotated data can be downloaded in various
community standard data exchange formats. These include
Proteomics Standards Initiative for Molecular Interaction
(PSI-MI version 2.5), Biological PAthway eXchange
(BioPAX level 3) and Systems Biology Markup Language
(SBML level 2.1). PSI-MI is a community standard for
molecular interaction data which facilitates data compari-
son, exchange and verification (55,56). BioPAX is an emer-
ging standard community language that enables
integration, exchange, visualization and analysis of bio-
logical pathway data which also incorporates information
that can be stored in the PSI-MI format (57). SBML is a
machine-readable format for representing models which
facilitates mathematical simulation (58). An excel file is
also provided to download the list of upregulated and
downregulated genes.
Visualization of the
RANKL/RANK-signaling pathway
RANKL pathway data which are made available using dif-
ferent community standards allows interoperability with
other data visualization and analysis software such as
Cytoscape (59), Ingenuity pathway analysis, Visualization
and layout services for BioPAX pathway models
(VISIBIOweb) (60) or Chisio BioPAX Editor (ChiBE) (61).
Moreover, various software tools are currently under devel-
opment which converts user-defined formats into these
standard formats. For example, conversion between
GenMAPP Pathway Markup Language (GPML) and stand-
ard pathway exchange formats such as SBML and BioPAX
are under development using Paxtools (62,63). A signaling
network of RANKL pathway can be created using cytoscape
by importing the BioPAX file. The number of steps
which leads to any reaction from the stimulated recep-
tor currently depends on the interconnectivity of mol-
ecules and their reactions reported in a pathway.
Thus, we hope that the RANKL pathway data available in
various data formats will help the computational as well as
basic biologist to visualize their own custom maps using
different pathway visualization tools available in the
community.
However, taking into account the heterogeneity and the
necessity for experimental validation of independent path-
way reactions, we have applied a set of stringent criteria to
select pathway reactions from the curated data to be de-
picted in a pathway map. The selection of such reactions
stimulated by RANK was based on any of the following
criteria: (i) availability of two or more research articles
which established a reaction, (ii) availability of two or
more different cell types in which a particular reaction
was demonstrated, (iii) proof for a PPIs as component of
known protein complexes, (iv) Whether reactions reported
using high-throughput experiments have a low-throughput
experimental support and (v) whether reactions were
represented in expert review articles with their biological
significance. A basic network model of the RANKL path-
way applying the above criteria was manually generated
using PathVisio software (Figure 2). A .gpml file with
Table 1. Protein complexes curated in RANKL/RANK signaling
Protein complex References
TNFRSF11A–TRAF6–TAB2–
MAP3K7–TAB1
Mizukami et al., 2002 (67)
TNFRSF11A–TRAF1–TRAF3–TRAF6 Wong et al., 1999 (68)
RUNX1–TRAF6–FHL2 Bai et al., 2008 (69)
TNFRSF11A–SRC–TRAF6 Wong et al., 1999 (68)
TNFRSF11A–CBL–PIK3R1–PIK3R2–TRAF6 Arron et al., 2001 (70)
TNFRSF11A–TAB1–MAP3K7 Mizukami et al., 2002 (67)
TNFRSF11A–TAB2–TRAF6 Mizukami et al., 2002 (67)
SQSTM1–TRAF6–CYLD Jin et al., 2008 (71)
LYN–TNFRSF11A–PTPN6–GAB2 Kim et al., 2009 (72)
IKBKG–IKBKG–IKBKG Darwech et al., 2009 (73)
The table contains a list of proteins which are reported to form
complexes when RANK (TNFRSF11A) is stimulated by RANKL
(TNFSF11). Five of the protein complexes which contained RANK
also had TRAF6 as a constituent molecule, indicating a central role
of TRAF6 in RANKL/RANK signaling.
.............................................................................................................................................................................................................................................................................................
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PTM status, site and residue of modification mapped to
specific RefSeq accession and PubMed identifiers are
also available to download at http://www.netpath.org/
netslim/rankl_pathway.html. A full view of RANKL pathway
image in html format is also available at the above link
with each node and edge hyperlinked to their correspond-
ing NetPath molecule page and literature evidences
respectively.
Update process
With the involvement of the pathway authority, the
RANKL/RANK pathway will be updated periodically as
more reactions become available. The proteins and the
microRNAs which are differentially regulated by activated
RANK will be curated in the future. We hope to get the
active participation from the scientific community to
update and improve the RANKL pathway reactions.
Conclusions
Curated and organized data pertaining to signaling path-
ways are crucial to understand biological processes and
gene regulation. This is especially true in the wake of
increasing use of high-throughput technologies to study
gene and protein expression as well as PTMs (64–66).
Combining such a pathway map with high-throughput
Figure 1. An overview of the RANKL pathway page in NetPath. RANKL pathway page in NetPath hosts the information on the
number of molecules curated for RANKL pathway, statistics of the total number of molecules, link to RANKL pathway reactions
and the list of genes which are differentially upregulated by RANKL/RANK pathway. Every molecule in the pathway page is
linked to the corresponding NetPath molecule page which is further linked to Entrez gene, HPRD, OMIM and Swiss-Prot iden-
tifiers. The reaction page of the RANKL pathway contains the list of each type of reactions such as physical interactions, enzyme
catalysis and transport with a brief description about the reactions with their PTM dependence or interacting regions/domains/
motifs whenever it was available in literature. The list of curators and reviewers are provided in the RANKL pathway page with
the details of the pathway authority. A comments tab is provided in the pathway page to invite the queries and suggestions
from the community so as to update and improve RANKL pathway alike other pathways in NetPath.
.............................................................................................................................................................................................................................................................................................
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.............................................................................................................................................................................................................................................................................................Figure 2. A high-confidence RANKL/RANK pathway reaction map using PathVisio. The RANKL/RANK pathway reaction map
represents the high-confidence molecular reactions induced by the binding of RANKL homotrimer to its homotrimer receptor
complex. The presented map of RANKL/RANK contains 43 proteins involved in 17 molecular associations, 24 enzyme catalysis
reactions and four translocation events. The nodes and edges represent the molecules and their reactions respectively. A detailed
legend representative of the information of different types of edges distinguished with various colors is provided. A download-
able version of this map is available with the description for each of the reactions and the inclusion criteria for selection of the
reaction in the map at http://www.netpath.org/netslim/rankl_pathway.html.
.............................................................................................................................................................................................................................................................................................
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ogy approaches. We anticipate that the RANKL/RANK sig-
naling pathway resource described here will help accelerate
research in both normal physiology as well as disease mech-
anisms. The RANKL/RANK pathway reactions are available
to download at (http://www.netpath.org/pathways?path_
id=NetPath_21). We encourage interested members of the
scientific community to help us improve the quality of the
information in NetPath by submitting their suggestions
and critical comments through http://www.netpath.org/
comments.
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